NCT07092748

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HS387 in Subjects With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Zhejiang Hisun Pharmaceutical Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)

Conditions

• Advanced Solid Cancers

Interventions

Type	Name	Description
DRUG	HS387	HS387 tablets will be given orally

Timeline

• Start date: 2025-07-15
• Primary completion: 2028-06-30
• Completion: 2028-12-31
• First posted: 2025-07-30
• Last updated: 2025-07-30

Locations

1 site across 1 country: China